Infliximab Biosimilar (Genor Biopharma)

英夫利西单抗生物类似药（嘉和生物药业）

Report date: 2022/03/02 14:57:40

Base Information

Drug NameInfliximab Biosimilar (Genor Biopharma)
Drug Alias Name英夫利西单抗生物仿制药（嘉和生物药业）佳佑健GB-242
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Global Approved IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Approved Indications in ChinaPsoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Original Approved Country/TerritoryMainland China
Original Approved Date2022/02/23
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenor Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYuxi Genor Biotechnology Co Ltd
Inactive CompaniesGenor Biopharma Co Ltd
Active IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksN/A